Reports Q1 revenue $620.4M, consensus $630.68M. “Astrana’s strong start to the year reflects the continued momentum behind our mission to build the nation’s leading patient-centered healthcare platform. Our differentiated clinical capabilities and technology-enabled delegated model continue to drive strong, profitable growth while delivering better outcomes for both patients and providers. Even in a complex regulatory and economic environment, we continue to prove that value-based care can deliver meaningful impact at scale with long-term sustainability,” said Brandon Sim, President and CEO of Astrana Health (ASTH).
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ASTH:
- MCOs’ ‘mixed messages’ creating volatility in value-based care, says Truist
- Astrana Health initiated with an Equal Weight at Barclays
- Astrana Health Appoints New Chief Accounting Officer
- Astrana Health price target lowered to $46 from $50 at Truist
- Astrana Health Highlights Strategic Acquisition Plans